Your session is about to expire
← Back to Search
Unknown
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Phase 2
Waitlist Available
Research Sponsored by Mitsubishi Tanabe Pharma America Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new medication called MT-2990 to see if it can help women who have moderate to severe pain from endometriosis. The women in the study have been diagnosed with endometriosis through surgery. The goal is to find out if MT-2990 is safe and effective in reducing their pain.
Eligible Conditions
- Dysmenorrhea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2021 Phase 2 trial • 76 Patients • NCT0384099311%
Urinary tract infection
8%
Blood creatine phosphokinase increased
5%
Headache
5%
Corona virus infection
5%
Vulvovaginal mycotic infection
5%
Ageusia
5%
Anosmia
5%
Abdominal pain upper
5%
Fatigue
5%
Infusion site pain
5%
Pain
5%
Back pain
3%
Localised infection
3%
Axillary pain
3%
Coronavirus test positive
3%
Breast tenderness
3%
Cough
3%
Gastrointestinal disorder
3%
Constipation
3%
Vomiting
3%
Upper respiratory tract infection
3%
Dysfunctional uterine bleeding
3%
Vulvovaginal pain
3%
Rhinorrhoea
3%
Chest pain
3%
Conjunctivitis
3%
Migraine
3%
Nipple pain
3%
Pain in extremity
3%
Fibrocystic breast disease
3%
Pharyngitis streptococcal
3%
Nausea
3%
Nasopharyngitis
3%
Urine analysis abnormal
3%
Decreased appetite
3%
Dysgeusia
3%
Meralgia paraesthetica
3%
Breast cyst
3%
Abortion induced
3%
Vertigo
3%
Abdominal distension
3%
Injection site haemorrhage
3%
Pyrexia
3%
Hypercholesterolaemia
3%
Arthralgia
3%
Mood swings
3%
Nightmare
3%
Restlessness
3%
Acne
3%
Flushing
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
MT-2990
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MT-2990Experimental Treatment1 Intervention
MT-2990, over 16 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo, over 16 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MT-2990
2019
Completed Phase 2
~200
Find a Location
Who is running the clinical trial?
Mitsubishi Tanabe Pharma America Inc.Lead Sponsor
26 Previous Clinical Trials
3,226 Total Patients Enrolled
Mitsubishi Tanabe Pharma Development America, Inc.Lead Sponsor
21 Previous Clinical Trials
2,556 Total Patients Enrolled
Head of Clinical Development,Study DirectorMitsubishi Tanabe Pharma America Inc.
7 Previous Clinical Trials
747 Total Patients Enrolled
Head of Medical ScienceStudy DirectorMitsubishi Tanabe Pharma America Inc.
17 Previous Clinical Trials
2,410 Total Patients Enrolled